Skip Navigation

Defense Health Agency

"On October 1, 2013, the Department of Defense established the Defense Health Agency (DHA) to manage the activities of the Military Health System. These activities include those previously managed by TRICARE Management Activity (TMA), which was disestablished on the same date. During the next several months, all TMA websites will change to reflect the new DHA. We appreciate your patience during this transition."
 

November 26, 2007 and March 10, 2008

Triptans

  1. Does the prior authorization described in condition set # C8201, requiring an adequate trial of sumatriptan, apply to formulary Triptans?


  2. Would there be a step for the BCF agent?


Osteoporosis Agents

  1. With the change to the NDAA, what is the group looking for in the quote document?

  2. Does the FCP need to be entered on the UF VARR document?

  3. The FCP pricing should not be higher then the Federal Ceiling Price?

  4. Why the enclosure of agents in this class?

  5. When you review the Osteoporosis class specific to the Cost Determination, will you evaluate the "weighted average cost" at the drug(strength) or will you evaluate the drug by (all strengths) for all POS's?

Newly Approved Drugs

  1. Is there a time line to the review of previous reviewed classes?

VARR

  1. No Questions

BPA

  1. No Questions

Quote Submissions

  1. When calculating the price on a package can we round up or do we need to cut off the price after two decimal points?

  2. Regarding FSS pricing, should it be from the Jan 1 date or the Current price?

Additional Questions

  1. When is the BAP Meeting?

  2. Policy and procedure, Could you expand on the changes?

  3. With the changes to the VARR, are we moving away from the WAC?

  4. In April, what is the conference going to cover?

  5. Where is the meeting announcement going to be posted?

  6. Will the announcement go out across more then one site?

  7. My question is in regards to Teriparatide (Forteo). For Teriparatide, I believe the figures presented in the tab titled "Historical" are in milliliters (e.g. 1, 744 total milliliters used in the MTF segment) while the figures presented in the tab titled "Utilization Data" are in pens (e.g. 581 total pens used in the MTF segment). Am I correct?


Triptans

  1. Does the prior authorization described in condition set # C8201, requiring an adequate trial of sumatriptan, apply to formulary Triptans?

    Yes, the prior authorization requires all new Triptan users to complete an adequate trial of a sumatriptan before a any other Triptan is provided to a new user through an MTF pharmacy, the TMOP, or a TRICARE retail network pharmacy.

    [Top]

  2. Would there be a step for the BCF agent?

    Yes, an adequate trial of sumatriptan would be required before the other BCF agent could be prescribed.

    [Top]

Osteoporosis Agents

  1. With the change to the NDAA, what is the group looking for in the quote document?

    It is important to provide pricing for all NDCs before submitting the quote. If a product is submitted without a price, the product will be evaluated at its current retail price.

    [Top]

  2. Does the FCP need to be entered on the UF VARR document?

    Yes, the manufacturer must submit a quote on the UF VARR document less than or equal to the FCP. If the manufacturer submits a quote on the UF VARR greater than FCP, the UF VARR agreement will not be executed by the Chief of Pharmaceutical Operations Directorate at TMA.

    [Top]

  3. The FCP pricing should not be higher then the Federal Ceiling Price?

    Yes

    [Top]

  4. Why the enclosure of agents in this class?

    We are including all of the agents that we have used in the past.

    [Top]

  5. When you review the Osteoporosis class specific to the Cost Determination, will you evaluate the "weighted average cost" at the drug(strength) or will you evaluate the drug by (all strengths) for all POS's?

    Cost will be based on the weighted average cost across all strengths and dosage forms.

    [Top]

Newly Approved Drugs

  1. Is there a time line to the review of previous reviewed classes?

    We will review drugs as soon as possible; we will be looking at all new drugs in a timely manner.

    [Top]

VARR

  1. No Questions

    [Top]

BPA

  1. No Questions

    [Top]

Quote Submissions

  1. When calculating the price on a package can we round up or do we need to cut off the price after two decimal points?

    Rounding for the Package price is OK.

    [Top]

  2. Regarding FSS pricing, should it be from the Jan 1 date or the Current price?

    The Jan 1, 2008 FSS price

    [Top]

Additional Questions

  1. When is the BAP Meeting?

    About 6 weeks following the June meeting. It is tentatively scheduled for 24 July 08 in the NCA.

    [Top]

  2. Policy and procedure, Could you expand on the changes?

    In early April the changes will be available.

    [Top]

  3. With the changes to the VARR, are we moving away from the WAC?

    Yes the documents on the web site under revision, but we are moving to the FCP.

    [Top]

  4. In April, what is the conference going to cover?

    It will talk about the Section 703 Refund legislation, policy, and procedures.

    [Top]

  5. Where is the meeting announcement going to be posted?

    It will be announced on the Federal Register. Site, http://www.gpoaccess.gov/fr/index.html.

    [Top]

  6. Will the announcement go out across more then one site?

    We'll be working with several groups to get the announcement out.

    [Top]

  7. My question is in regards to Teriparatide (Forteo). For Teriparatide, I believe the figures presented in the tab titled "Historical" are in milliliters (e.g. 1, 744 total milliliters used in the MTF segment) while the figures presented in the tab titled "Utilization Data" are in pens (e.g. 581 total pens used in the MTF segment). Am I correct?

    In regards to teriparatide, the figures presented in the tab titled "Historical" are in milliliters and the figures presented in the tab titled "Utilization Data" are in pens.

    [Top]